Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
20 déc. 2021 07h59 HE
|
Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
Exactus, Inc. Signs Cool & Dre Endorsement and Co-Branding Deal
26 nov. 2019 06h30 HE
|
Exactus, Inc.
DELRAY BEACH, Fla., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB:EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today...
Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment
14 févr. 2018 07h00 HE
|
Regentys
MIAMI LAKES, Fla., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Regentys (formerly Asana Medical, Inc.), a regenerative medicine company, today announced it will partner with Cook Biotech Inc., a world leader...
Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100
17 janv. 2018 08h00 HE
|
Vitality Biopharma, Inc
LOS ANGELES, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC
03 janv. 2018 08h30 HE
|
Vitality Biopharma, Inc
LOS ANGELES, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis
30 mai 2017 08h00 HE
|
Atlantic Healthcare plc
CAMBRIDGE, U.K., May 30, 2017 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)...
Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication
22 mai 2017 08h00 HE
|
Atlantic Healthcare plc
CAMBRIDGE, U.K., May 22, 2017 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)...
Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease
11 juin 2013 16h22 HE
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...
Early Diagnosis and Public Awareness of Crohn's and Ulcerative Colitis Critical to Patient Care
23 nov. 2011 09h00 HE
|
Crohn's & Colitis Foundation of Canada (CCFC)
TORONTO, ONTARIO--(Marketwire - Nov. 23, 2011) - Imagine experiencing agonizing and debilitating pain that lasts for hours, months and even a year without a Doctor or Medical Practitioner...